Comment on "Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project". [Response to Letter]

Clin Epidemiol. 2024 Jun 26:16:445-446. doi: 10.2147/CLEP.S482719. eCollection 2024.
No abstract available

Publication types

  • Comment

Grants and funding

This study was funded by the Italian Medicines Agency in the context of the multiregional pharmacovigilance project (AIFA 2012–2014: Post-marketing evaluation of the benefit–risk profile of originator biologics and biosimilars in the dermatological, rheumatological, gastroenterological and onco-hematological areas through the establishment of a single multiregional network for the integrated analysis of data from health databases, active surveillance and clinical registers – VALORE project). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.